Bridging Innovation & Collaboration:
The Future of Targeted Therapeutics

June 11

From 9 AM To 9 PM EDT

The Westin Waltham Boston
70 3rd Ave, Waltham, MA 02451
Biocytogen Symposium 2026 brings together leading minds from the biotech, pharma, and investment sectors for a high-impact exchange at the forefront of therapeutic innovation. The program will spotlight novel targets, emerging modalities, evolving regulatory landscapes, and next-generation strategies—including the growing role of AI and automation in drug discovery.
Speakers & Panelists

Dinesh Bangari, Ph.D., DACVP

Head of Discovery Pathology & Multimodal Imaging

Sanofi

Patrick Baeuerle, Ph.D.

Chief Scientific Advisor and Chairman of Scientific Advisory Board

Cullinan Therapeutics

Jacob Oppenheim, Ph.D.

Venture Partner

RA Ventures (RAVen)

Yaobin Liu, Ph.D.

Director

Incyte

Robert Tighe

SVP, Preclinical and Translational Sciences

Ottimo Pharma

Andrew Steinsapir

Director, Gene Therapy Program Lead

Deerfield

Acting Chief Technology Officer

Apertura Gene Therapy

Wade Blair, Ph.D.

CSO

IntegerBio

Bruce Turner, M.D., Ph.D.

CEO

Xanadu Bio/lso Bio

Emory Werner, M.D.

Investment Director, Invest Venture

RA Capital

Alex Cogdill, Ph.D., MEng

Head of Strategic Initiatives, Global Business Development

Daiichi Sankyo US

Hong Chen, Ph.D.

Director of Search and Evaluation

Novo Nordisk

Nikhil Mutyal, Ph.D.

Head of Search & Evaluation for Respiratory & Immunology

AstraZeneca

Uli Stilz, Ph.D.

Senior Advisor

Flagship Pioneering

Zhihong Li, Ph.D.

Ex-FDA Reviewer & Chief Development Officer

Core Guided Therapeutics

Yuelei Shen, Ph.D.

President & CEO

Biocytogen

Madeline Lee

Chief Operating Officer

Biocytogen

Frank An, Ph.D.

VP of the Institute for Biologics

Biocytogen

Icy Niu

Executive Director, Global Business & Marketing Head

Biocytogen

Agenda

THURSDAY,
JUNE 11, 2026
9 AM-9 PM

MORNING SESSIONS: PRECLINICAL & TRANSLATIONAL INNOVATION

  • 08:30-09:00

    Check-in

  • 09:00-09:15

    Opening Remarks
    Yuelei Shen, Ph.D.President & CEOBiocytogen

  • 09:15-09:45

    Keynote 1: Preclinical development of OTP-01: A Unique Bifunctional PD-1/VEGFR2 Inhibitor
    Robert TigheSVP, Preclinical and Translational SciencesOttimo Pharma

  • 09:45-10:15

    Keynote 2: Future of ADC Development-Novel Targets and Biologic Structure
    Bruce Turner, M.D., Ph.D.CEOXanadu Bio/Iso Bio

  • 10:15-10:45

    Keynote 3: T Cell-Engaging Antibodies, A Therapeutic Modality on the Rise
    Patrick Baeuerle, Ph.D.Chief Scientific Advisor and Chairman of Scientific Advisory BoardCullinan Therapeutics

  • 10:45-11:45

    Scientific Panel 1: New Targets, New Modalities: From Discovery to Clinical Success
    Moderator
    Frank An, Ph.D.VP of the Institute for BiologicsBiocytogen
    Panelists
    Rob Tighe (Ottimo Pharma)
    Bruce Turner (Xanadu Bio/Iso Bio)
    Uli Stilz (Flagship)
    Patrick Baeuerle (Cullinan Therapeutics)

  • 11:45-12:15

    Keynote 4: RenSuper Workstation: An AI-Driven Antibody Discovery Platform From Target to Antibody Leads in Click
    Icy NiuExecutive Director, Global Business & Marketing HeadBiocytogen

  • 12:15-13:00

    Lunch Break

AFTERNOON SESSIONS: TRANSLATIONAL STRATEGY & DECISION-MAKING

  • 13:00-13:30

    Keynote 5: Translational Research in Drug Discovery: Bridging Biology, Models and Intelligence
    Dinesh Bangari, Ph.D.Head of Discovery Pathology & Multimodal ImagingSanofi

  • 13:30-14:00

    Keynote 6: Engineering Biology: Therapeutics Development for 2026
    Jacob Oppenheim, Ph.DVenture PartnerRA Ventures (RAVen)

  • 14:00-14:45

    Leading the Antibody+ Era through Global Capital and Strategic Partnerships
    Moderator
    Yuelei Shen, Ph.D.President & CEOBiocytogen
    Panelists
    Emory Werner (RA Capital)
    Nikhil Mutyal (AstraZeneca)
    Hong Chen (Novo Nordisk)
    Alex Cogdill (Daiichi Sankyo US)

  • 14:45-15:00

    Coffee Break

  • 15:00-15:30

    Keynote 7: Understanding of FDA’s Latest Position on Oncology Drug Approvals-the Pivotal Trial
    Zhihong Li, Ph.D.Ex FDA Reviewer & Chief Development OfficerCore Guided Therapeutics

  • 15:30-16:00

    Keynote 8: Synthetic Interferons Demonstrate Potent Antiviral and Anti-Tumor Activity with the Potential for an Improved Safety Profile
    Wade Blair, Ph.D.CSOIntegerBio

  • 16:00-16:15

    Keynote 9: INCA036873, a First-in-Class CD70×CD3 T Cell–Redirecting Bispecific Antibody for the Treatment of CD70-Positive Malignancies
    Yaobin LiuDirectorIncyte

  • 16:15-16:45

    Keynote 10: TfR1 CapX™ - Leveraging the Human Transferrin Receptor to Unlock the CNS in AAV Gene Therapy
    Andrew SteinsapirDirector, Gene Therapy Program LeadDeerfield Management

  • 16:45-17:30

    Scientific Panel 2: Predictive Toxicology, Translational Strategy, and Regulatory Decision-Making
    Moderator
    Madeline LeeChief Operating OfficerBiocytogen
    Panelists
    Wade Blair (IntegerBio)
    Yaobin Liu (Incyte)
    Andrew Steinsapir (Deerfield)
    Zhihong Li (Core Guided Therapeutis)

  • 17:30-18:00

    Executive Dinner & Happy Hour

  • 18:00-21:00

    Transition to Biocytogen Facility
The registration has reached the limit. Please stay tuned for our upcoming event!